Vivian

Vivian asked for clarification on the specific indications NeoGenomics is pursuing for RaDaR ST beyond the currently approved head and neck and breast cancers, and the expected cadence of reimbursement and further milestones for 2026.

Answer

CEO Tony Zook confirmed current indications as HPV negative adjuvant surveillance in head and neck and HR positive/HER2 negative surveillance five years out in breast cancer. He stated intentions for additional indication submissions for RaDaR ST, without specifying them, and highlighted the ongoing next-gen MRD program for ultra-sensitive options in low-shedding cancers. Tony Zook expects these new indication submissions to manifest in the second half of 2026, avoiding redundancy with the next-gen program.

Vivian asked for a reminder of the indications NeoGenomics is pursuing for Radar ST beyond head and neck and breast cancer. She also inquired about the expected cadence of reimbursement for these indications and any further milestones to look for in 2026.

Answer

CEO Tony Zook confirmed the two current indications are subsets of HPV-negative adjuvant surveillance in head and neck cancer and HR-positive, HER2-negative surveillance five years out in breast cancer. He stated the company plans additional submissions for indication expansion for Radar ST, without specifying for competitive reasons. He also mentioned the ongoing next-gen MRD program, which aims for ultra-sensitive options for low-shedding cancers, with new indication submissions expected in the short term and potential manifestation in H2 2026.